Oncolytic virus as a cancer stem cell killer: progress and challenges

Area of Science:

• Oncology
• Virology
• Cancer Stem Cell Biology

Background:

• Oncolytic viruses (OVs) are engineered or naturally occurring viruses that selectively infect and kill cancer cells while sparing normal cells.
• Conventional cancer therapies often lack specificity, leading to side effects and relapse, partly due to the resistance of cancer stem cells (CSCs).
• CSCs possess self-renewal and differentiation capabilities, contributing to therapy resistance and tumor recurrence.

Purpose of the Study:

• To review recent studies on the application of oncolytic viruses for targeting cancer stem cells.
• To explore the potential of OVs as a therapeutic strategy against CSCs.
• To discuss challenges and future perspectives in OV-based CSC therapy.

Main Methods:

• Literature review of recent studies investigating oncolytic viruses and cancer stem cells.
• Analysis of proposed mechanisms by which OVs may overcome CSC resistance.
• Examination of viral strategies for targeting CSC-specific features or self-renewal properties.

Main Results:

• Initial studies indicate that oncolytic viruses can effectively target cancer stem cells across various tumor types.
• OVs may bypass common resistance mechanisms associated with chemotherapy and radiation.
• Viruses can be engineered to express therapeutic transgenes that target CSCs.

Conclusions:

• Oncolytic virotherapy presents a promising and specific approach for eliminating cancer stem cells.
• Further research is needed to address challenges and optimize OV-based strategies for CSC eradication.
• OVs offer a potential avenue to overcome treatment resistance and prevent cancer relapse.